Speaker Profile
Biography
Dr Regev joined Genentech in August 2020 as Head and Executive Vice President, Genentech Research and Early Development. In this role, she is responsible for the management of all aspects of gRED’s drug discovery and drug development activities. In addition, Dr Regev is a member of the Genentech Executive Committee and Board of Directors, and a member of the expanded Corporate Executive Committee for Roche. She also run an active research lab focused on developing and applying experimental methods and computational algorithms to decipher intra- and intercellular circuits in cells in tissues.
Prior to Genentech, Dr. Regev served as Chair of the Faculty, Core Institute Member (currently on leave), Founding Director of the Klarman Cell Observatory, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT (currently on leave) and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.




